Disclaimer
The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.
Chief Executive Officer
“Today’s private placement demonstrates the strength of Sequana Medical and the appeal of our investment case, bringing our alfapump® platform to address clear unmet medical needs of liver disease and heart failure patients. The continued support of our existing investors, as well as new experienced life sciences investors and industry experts, is an endorsement of the strong progress we have made over the last year. The proceeds of the transaction will enable us to continue to progress towards launching alfapump® for the treatment of recurrent or refractory liver ascites in the U.S., which we expect in H1 2022, as well as driving forward the clinical development of alfapump® DSR as a potential chronic therapy for heart failure patients who are not well controlled on diuretics.”
JUNE 25, 2020
Download document
JUNE 25, 2020
Sequana Medical announces listing of 644,287 existing shares on Euronext Brussels following January 2020 Equity Placement
JANUARY 29, 2020
Sequana Medical announces new share capital amount and new number of shares
JANUARY 22, 2020
Sequana Medical successfully raises EUR 19.0 million
JANUARY 22, 2020
Sequana Medical Launches Equity Placement
Email: IR@sequanamedical.com
Tel: +32 498 053579
